Michael C. Heinrich, M.D.

  • Professor of Medicine, School of Medicine
  • Cell and Developmental Biology Graduate Program, School of Medicine
  • Cancer Biology Graduate Program, School of Medicine
  • Program in Molecular and Cellular Biosciences, School of Medicine

Biography

Dr. Heinrich's research includes both preclinical identification of novel molecular targets and testing of new agents in the laboratory and the clinic. This includes both genomics research using high-throughput gentoyping to identify oncogenic mutations and testing of new compounds in cellular and biochemical assays. Dr. Heinrich’s laboratory is particularly expert in the analysis of inhibitors of oncogenic receptor tyrosine kinases such as KIT, PDGFRA and FLT3.

Education and training

  • Degrees

    • M.D., 1984, Johns Hopkins University School of Medicine

  • Residency

    • Oregon Health & Science University, 1988

  • Fellowship

    • Hematology/medical oncology, Oregon Health & Science University, 1991

  • Certifications

    • American Board of Internal Medicine, (internal medicine) 1987

Memberships and associations:

  • American Society of Clinical Oncology

Publications

Elsevier pure profile

Publications

  • Adjuvant imatinib in high-risk resected gastrointestinal stromal tumors

    Journal of surgical oncology
    1. Thomas L. Sutton
    2. Kevin G. Billingsley
    3. Alicia J. Johnson
    4. Christopher L. Corless
    5. Charles D. Blanke
    6. Michael C. Heinrich
    7. Skye C. Mayo

  • A Novel Human SDHA-Knockout Cell Line Model for the Functional Analysis of Clinically Relevant SDHA Variants

    Clinical Cancer Research
    1. Jason D. Kent
    2. Lillian R. Klug
    3. Michael C. Heinrich

  • Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor

    Leukemia
    1. Jorge E. Cortes
    2. Koji Sasaki
    3. Dong Wook Kim
    4. Timothy P. Hughes
    5. Gabriel Etienne
    6. Michael J. Mauro
    7. Andreas Hochhaus
    8. Fabian Lang
    9. Michael C. Heinrich
    10. Massimo Breccia
    11. Michael Deininger
    12. Yeow Tee Goh
    13. Jeroen J.W.M. Janssen
    14. Moshe Talpaz
    15. Valle Gomez Garcia de Soria
    16. Philipp le Coutre
    17. Daniel J. DeAngelo
    18. Andrea Damon
    19. Silvia Cacciatore
    20. Fotis Polydoros
    21. Nithya Agrawal
    22. Delphine Rea

  • Avapritinib treatment of aggressive systemic mastocytosis with a novel KIT exon 17 mutation

    Leukemia Research Reports
    1. Lyndsey Sandow
    2. Ajia Town
    3. Michael C. Heinrich

  • Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors

    Clinical Cancer Research
    1. Michael C. Heinrich
    2. Xinhua Zhang
    3. Robin L. Jones
    4. Suzanne George
    5. César Serrano
    6. Yanhong Deng
    7. Sebastian Bauer
    8. Shirong Cai
    9. Xin Wu
    10. Yongjian Zhou
    11. Kaixiong Tao
    12. Zhichao Zheng
    13. Jun Zhang
    14. Yuehong Cui
    15. Hui Cao
    16. Meining Wang
    17. Jin Hu
    18. Jason Yang
    19. Jian Li
    20. Lin Shen

  • KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor

    Journal of Clinical Oncology
    1. Thomas Mühlenberg
    2. Johanna Falkenhorst
    3. Tom Schulz
    4. Benjamin S. Fletcher
    5. Alina Teuber
    6. Dawid Krzeciesa
    7. Isabella Klooster
    8. Meijun Lundberg
    9. Lydia Wilson
    10. Jonas Lategahn
    11. Margaret Von Mehren
    12. Susanne Grunewald
    13. Alicia Isabell Tüns
    14. Eva Wardelmann
    15. Jason K. Sicklick
    16. Mehdi Brahmi
    17. César Serrano
    18. Hans Ulrich Schildhaus
    19. Sonja Sievers
    20. Jürgen Treckmann
    21. Michael C. Heinrich
    22. Chandrajit P. Raut
    23. Wen Bin Ou
    24. Adrian Marino-Enriquez
    25. Suzanne George
    26. Daniel Rauh
    27. Jonathan A. Fletcher
    28. Sebastian Bauer

  • Outcomes of Late-Line Systemic Treatment in GIST

    Cancers
    1. Prapassorn Thirasastr
    2. Thomas L. Sutton
    3. Cissimol P. Joseph
    4. Heather Lin
    5. Behrang Amini
    6. Skye C. Mayo
    7. Dejka Araujo
    8. Robert S. Benjamin
    9. Anthony P. Conley
    10. John A. Livingston
    11. Joseph Ludwig
    12. Shreyaskumar Patel
    13. Ravin Ratan
    14. Vinod Ravi
    15. Maria A. Zarzour
    16. Elise F. Nassif Haddad
    17. Michael S. Nakazawa
    18. Xiao Zhou
    19. Michael C. Heinrich
    20. Neeta Somaiah

  • Ripretinib versus sunitinib in gastrointestinal stromal tumor

    Nature medicine
    1. Michael C. Heinrich
    2. Robin L. Jones
    3. Suzanne George
    4. Hans Gelderblom
    5. Patrick Schöffski
    6. Margaret von Mehren
    7. John R. Zalcberg
    8. Yoon Koo Kang
    9. Albiruni Abdul Razak
    10. Jonathan Trent
    11. Steven Attia
    12. Axel Le Cesne
    13. Brittany L. Siontis
    14. David Goldstein
    15. Kjetil Boye
    16. Cesar Sanchez
    17. Neeltje Steeghs
    18. Piotr Rutkowski
    19. Mihaela Druta
    20. César Serrano
    21. Neeta Somaiah
    22. Ping Chi
    23. William Reichmann
    24. Kam Sprott
    25. Haroun Achour
    26. Matthew L. Sherman
    27. Rodrigo Ruiz-Soto
    28. Jean Yves Blay
    29. Sebastian Bauer

  • The INSIGHT study

    Future Oncology
    1. Suzanne George
    2. Jean Yves Blay
    3. Ping Chi
    4. Robin L. Jones
    5. César Serrano
    6. Neeta Somaiah
    7. Hans Gelderblom
    8. John R. Zalcberg
    9. William Reichmann
    10. Kam Sprott
    11. Paulina Cox
    12. Matthew L. Sherman
    13. Rodrigo Ruiz-Soto
    14. Michael C. Heinrich
    15. Sebastian Bauer

  • Treatment of BRAF V600E mutant gastrointestinal stromal tumor with dabrafenib

    Journal of Gastrointestinal Oncology
    1. Sonia Gowda
    2. Lyndsey Sandow
    3. Michael C. Heinrich

  • A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor

    Clinical Cancer Research
    1. Suzanne George
    2. Michael C. Heinrich
    3. Neeta Somaiah
    4. Peter Oppelt
    5. Robert McLeod
    6. Satoshi Nishioka
    7. Madan G. Kundu
    8. Xiaozhong Qian
    9. Prasanna Kumar
    10. Abderrahmane Laadem
    11. Yvonne Lau
    12. Brittany P. Tran
    13. Maura Fallon
    14. Ololade Dosunmu
    15. Julia Shi
    16. Yoichi Naito

  • Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

    Leukemia
    1. Michael J. Mauro
    2. Timothy P. Hughes
    3. Dong Wook Kim
    4. Delphine Rea
    5. Jorge E. Cortes
    6. Andreas Hochhaus
    7. Koji Sasaki
    8. Massimo Breccia
    9. Moshe Talpaz
    10. Oliver Ottmann
    11. Hironobu Minami
    12. Yeow Tee Goh
    13. Daniel J. DeAngelo
    14. Michael C. Heinrich
    15. Valle Gómez-García de Soria
    16. Philipp le Coutre
    17. Francois Xavier Mahon
    18. Jeroen J.W.M. Janssen
    19. Michael Deininger
    20. Naranie Shanmuganathan
    21. Mark B. Geyer
    22. Silvia Cacciatore
    23. Fotis Polydoros
    24. Nithya Agrawal
    25. Matthias Hoch
    26. Fabian Lang

  • Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia

    Leukemia Research Reports
    1. Lyndsey Sandow
    2. Michael Heinrich

  • Circulating tumor DNA analysis of the phase III VOYAGER trial

    Annals of Oncology
    1. C. Serrano
    2. S. Bauer
    3. D. Gómez-Peregrina
    4. Y. K. Kang
    5. R. L. Jones
    6. P. Rutkowski
    7. O. Mir
    8. M. C. Heinrich
    9. W. D. Tap
    10. K. Newberry
    11. A. Grassian
    12. H. Shi
    13. S. Bialick
    14. P. Schöffski
    15. M. A. Pantaleo
    16. M. von Mehren
    17. J. C. Trent
    18. S. George

  • Kinase Mutations and Imatinib Response in Patients with Metastatic Gastrointestinal Stromal Tumor

    Journal of Clinical Oncology
    1. Michael C. Heinrich
    2. Christopher L. Corless
    3. George D. Demetri
    4. Charles D. Blanke
    5. Margaret Von Mehren
    6. Heikki Joensuu
    7. Laura S. McGreevey
    8. Chang Jie Chen
    9. Annick D. Van Den Abbeele
    10. Brian J. Druker
    11. Beate Kiese
    12. Burton Eisenberg
    13. Peter J. Roberts
    14. Samuel Singer
    15. Christopher D.M. Fletcher
    16. Sandra Silberman
    17. Sasa Dimitrijevic
    18. Jonathan A. Fletcher

  • Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study

    European Journal of Cancer
    1. Hans Gelderblom
    2. Robin L. Jones
    3. Jean Yves Blay
    4. Suzanne George
    5. Margaret von Mehren
    6. John R. Zalcberg
    7. Yoon Koo Kang
    8. Albiruni Abdul Razak
    9. Jonathan Trent
    10. Steven Attia
    11. Axel Le Cesne
    12. Brittany L. Siontis
    13. David Goldstein
    14. Kjetil Boye
    15. Cesar Sanchez
    16. Neeltje Steeghs
    17. Piotr Rutkowski
    18. Mihaela Druta
    19. César Serrano
    20. Neeta Somaiah
    21. Ping Chi
    22. Brooke Harrow
    23. Claus Becker
    24. William Reichmann
    25. Matthew L. Sherman
    26. Rodrigo Ruiz-Soto
    27. Michael C. Heinrich
    28. Sebastian Bauer

  • A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor

    BMC cancer
    1. Maria A. Pantaleo
    2. Michael C. Heinrich
    3. Antoine Italiano
    4. Claudia Valverde
    5. Patrick Schöffski
    6. Giovanni Grignani
    7. Anna K.L. Reyners
    8. Sebastian Bauer
    9. Peter Reichardt
    10. Daniel Stark
    11. Ghimja Berhanu
    12. Ulrike Brandt
    13. Tommaso Stefanelli
    14. Hans Gelderblom

  • CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation

    Clinical Lymphoma, Myeloma and Leukemia
    1. Timothy P. Hughes
    2. Jorge E. Cortes
    3. Delphine Réa
    4. Michael J. Mauro
    5. Andreas Hochhaus
    6. Dong Wook Kim
    7. Koji Sasaki
    8. Fabian Lang
    9. Michael C. Heinrich
    10. Massimo Breccia
    11. Michael Deininger
    12. Yeow Tee Goh
    13. Jeroen J.W.M. Janssen
    14. Moshe Talpaz
    15. Philipp le Coutre
    16. Shruti Kapoor
    17. Silvia Cacciatore
    18. Fotis Polydoros
    19. Nithya Agrawal
    20. Francois Xavier Mahon

  • Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response

    Clinical Cancer Research
    1. Mayra Yebra
    2. Shruti Bhargava
    3. Avi Kumar
    4. Adam M. Burgoyne
    5. Chih Min Tang
    6. Hyunho Yoon
    7. Sudeep Banerjee
    8. Joseph Aguilera
    9. Thekla Cordes
    10. Vipul Sheth
    11. Sangkyu Noh
    12. Rowan Ustoy
    13. Sam Li
    14. Sunil J. Advani
    15. Christopher L. Corless
    16. Michael C. Heinrich
    17. Razelle Kurzrock
    18. Scott M. Lippman
    19. Paul T. Fanta
    20. Olivier Harismendy
    21. Christian Metallo
    22. Jason K. Sicklick

  • Hepatic metastases in gastrointestinal stromal tumors

    HPB
    1. Thomas L. Sutton
    2. Brett S. Walker
    3. Kevin Billingsley
    4. Brett C. Sheppard
    5. Christopher L. Corless
    6. Michael C. Heinrich
    7. Skye C. Mayo

  • Neoadjuvant tyrosine kinase inhibitor therapy for patients with gastrointestinal stromal tumor

    American journal of surgery
    1. Liam H. Wong
    2. Thomas L. Sutton
    3. Brett C. Sheppard
    4. Christopher L. Corless
    5. Michael C. Heinrich
    6. Skye C. Mayo

  • Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting

    BMC cancer
    1. Patrick Schöffski
    2. Suzanne George
    3. Michael C. Heinrich
    4. John R. Zalcberg
    5. Sebastian Bauer
    6. Hans Gelderblom
    7. César Serrano
    8. Robin L. Jones
    9. Steven Attia
    10. Gina D’Amato
    11. Ping Chi
    12. Peter Reichardt
    13. Claus Becker
    14. Kelvin Shi
    15. Julie Meade
    16. Rodrigo Ruiz-Soto
    17. Jean Yves Blay
    18. Margaret von Mehren

  • Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors

    Clinical Cancer Research
    1. Suzanne George
    2. Margaret von Mehren
    3. Jonathan A. Fletcher
    4. Jichao Sun
    5. Sen Zhang
    6. Justin R. Pritchard
    7. John Graeme Hodgson
    8. David Kerstein
    9. Victor M. Rivera
    10. Frank G. Haluska
    11. Michael C. Heinrich